China issues a third ban to prevent the spread of mad cow disease through drugs

Introduction: China's State Food and Drug Administration today issued a third ban on "mad cow disease" in order to strengthen the supervision and management of bovine origin and related drugs, and ensure the safety of clinical medication Xinhua quoted a person from the State Food and drug administration as saying that from now on, China will ban the import of cattle derived materials for the preparation of Chinese patent medicines, such as natural bezoar, cattle gall cream, cattle bone powder, etc.; and prohibit the use of gelatin prepared from cattle bone in countries with BSE epidemic for drug production raw materials, excipients, shaping agents and hollow capsules Since then, the State Food and drug administration has suspended the acceptance of new bovine drugs and the application for the registration certificate of imported drugs for blood products made from human plasma of countries with BSE epidemic, the person said When applying for import drug registration certificate for blood products produced abroad, other biological products using human albumin as stabilizer and protectant, or blood products having obtained import drug registration certificate, the official certification document that the blood product preparation raw material plasma comes from the country without BSE epidemic situation must be provided For the manufacturers of bio extracted drugs, bio products, blood products, Chinese patent medicines and other varieties that have obtained the import drug registration certificate, the State Food and drug administration requires that they must, before October 1 this year, use the raw materials, excipients, dosage forms that do not use cattle derived materials for drugs, or use cattle derived materials, human plasma from countries that have not suffered from BSE epidemic The official documents of the family shall be submitted to the State Food and Drug Administration for the record In order to prevent the spread of "mad cow disease" through drug use, the State Food and Drug Administration issued a circular in 2000 and 2001, which made clear provisions on relevant issues.